Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide ...
After blind review by community volunteers of the initial Lilly Endowment Community Scholarship applications, nine finalists were selected — six young women and three young men. This year’s finalists ...
Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company could benefit from the government coverage of its weight loss medicines.
One day removed from earning a tie for the No. 1 spot in the Class 3A Associated Press rankings, the Effingham Flaming Hearts had the challenge of facing a tough Mt. Vernon team, albeit at Effingham ...
Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly ...